Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib in CML-CP Post Imatinib Failure
NCT04677439Phase 4Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Flumatinib in chronic myeloid leukemia (CML), sponsored by Shenzhen Second People's Hospital. Status: unknown.
02
Drugs
Flumatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04677439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677439.